Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 818

1.

Cardiovascular Protection with Anti-hyperglycemic Agents.

Deedwania P, Acharya T.

Am J Cardiovasc Drugs. 2019 Feb 15. doi: 10.1007/s40256-019-00325-9. [Epub ahead of print] Review.

PMID:
30767126
2.

Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction.

Lee CH, Tsai TH, Lin CJ, Hsueh SK, Chung WJ, Cheng CI.

Am J Cardiovasc Drugs. 2019 Feb 12. doi: 10.1007/s40256-018-00318-0. [Epub ahead of print]

PMID:
30746615
3.

Correction to: Plasma Vitamin K1 Levels in Italian Patients Receiving Oral Anticoagulant Therapy for Mechanical Heart Prosthesis: A Case-Control Study.

Cafolla A, Gentili A, Cafolla C, Perez V, Baldacci E, Pasqualetti D, Demasi B, Curini R.

Am J Cardiovasc Drugs. 2019 Feb 9. doi: 10.1007/s40256-019-00331-x. [Epub ahead of print]

PMID:
30739300
4.

Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.

Feng Y, Huang R, Kavanagh J, Li L, Zeng X, Li Y, Fu P.

Am J Cardiovasc Drugs. 2019 Feb 9. doi: 10.1007/s40256-018-00321-5. [Epub ahead of print] Review.

PMID:
30737754
5.

Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination.

Han SN, Yang WH, Yin JJ, Tao HL, Zhang LR.

Am J Cardiovasc Drugs. 2019 Feb 4. doi: 10.1007/s40256-018-00317-1. [Epub ahead of print] Review.

PMID:
30714088
6.

Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise.

Braschi A.

Am J Cardiovasc Drugs. 2019 Feb 4. doi: 10.1007/s40256-018-00316-2. [Epub ahead of print] Review.

PMID:
30714087
7.

How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?

Schooling CM, Zhao JV.

Am J Cardiovasc Drugs. 2019 Jan 29. doi: 10.1007/s40256-018-00315-3. [Epub ahead of print]

PMID:
30693439
8.

Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.

Nicholls SJ, Nelson AJ.

Am J Cardiovasc Drugs. 2019 Jan 25. doi: 10.1007/s40256-018-00322-4. [Epub ahead of print] Review.

PMID:
30680652
9.

Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.

Demerouti E, Karyofyllis P, Manginas A, Anthi A, Karatasakis G, Athanassopoulos G, Voudris V.

Am J Cardiovasc Drugs. 2019 Jan 23. doi: 10.1007/s40256-018-00319-z. [Epub ahead of print]

PMID:
30671881
10.

Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects.

Goyal N, Skrdla P, Schroyer R, Kumar S, Fernando D, Oughton A, Norton N, Sprecher DL, Cheriyan J.

Am J Cardiovasc Drugs. 2019 Jan 14. doi: 10.1007/s40256-018-00320-6. [Epub ahead of print]

PMID:
30637626
11.

Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?

Nicholls SJ, Nelson AJ.

Am J Cardiovasc Drugs. 2019 Jan 5. doi: 10.1007/s40256-018-00323-3. [Epub ahead of print]

PMID:
30610681
12.

Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs.

Takata K, Nicholls SJ.

Am J Cardiovasc Drugs. 2018 Dec 19. doi: 10.1007/s40256-018-0312-1. [Epub ahead of print] Review.

PMID:
30565156
13.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).

Sugawara M, Goto Y, Yamazaki T, Teramoto T, Oikawa S, Shimada K, Uchiyama S, Ando K, Ishizuka N, Murata M, Yokoyama K, Uemura Y, Ikeda Y; Japanese Primary Prevention Project (JPPP) Study Group.

Am J Cardiovasc Drugs. 2018 Dec 18. doi: 10.1007/s40256-018-0313-0. [Epub ahead of print]

PMID:
30565155
14.

Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis.

Leclerc J, Blais C, Rochette L, Hamel D, Guénette L, Poirier P.

Am J Cardiovasc Drugs. 2018 Nov 24. doi: 10.1007/s40256-018-0309-9. [Epub ahead of print]

PMID:
30471054
15.

DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.

Chen YC, Lin FY, Lin YW, Cheng SM, Lin RH, Chuang CL, Sheu JS, Chen SM, Chang CC, Tsai CS.

Am J Cardiovasc Drugs. 2019 Feb;19(1):75-86. doi: 10.1007/s40256-018-0302-3.

PMID:
30467686
16.

Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial : The CLAU Randomized Trial Long-Term Outcome.

De Haro J, Bleda S, Gonzalez-Hidalgo C, Michel I, Acin F.

Am J Cardiovasc Drugs. 2018 Nov 12. doi: 10.1007/s40256-018-0307-y. [Epub ahead of print]

PMID:
30417231
17.

Optimal Medical Therapy Prescribing Patterns and Disparities Identified in Patients with Acute Coronary Syndromes at an Academic Medical Center in an Area with High Coronary Heart Disease-Related Mortality.

Fox AN, Skrepnek GH, Miller JL, Schwier NC, Ripley TL.

Am J Cardiovasc Drugs. 2018 Nov 10. doi: 10.1007/s40256-018-0308-x. [Epub ahead of print]

PMID:
30414088
18.

Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients.

Sheikh-Taha M, Deeb ME.

Am J Cardiovasc Drugs. 2018 Nov 8. doi: 10.1007/s40256-018-0310-3. [Epub ahead of print]

PMID:
30406915
19.

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine.

Lapostolle F, Van't Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet JP, Silvain J, Lassen JF, Heutz WMJM, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Ten Berg J, Zeymer U, Licour M, Tsatsaris A, Montalescot G; ATLANTIC Investigators.

Am J Cardiovasc Drugs. 2018 Oct 23. doi: 10.1007/s40256-018-0305-0. [Epub ahead of print]

PMID:
30353444
20.

Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.

Huet F, Akodad M, Kalmanovitch E, Adda J, Agullo A, Batistella P, Roubille C, Roubille F.

Am J Cardiovasc Drugs. 2019 Feb;19(1):1-10. doi: 10.1007/s40256-018-0306-z.

PMID:
30345485

Supplemental Content

Loading ...
Support Center